Bio-Techne Misses Again as Emerging Biotech Spending Deteriorates Further, Masking Genuine Bright Spots in Cell Therapy and Spatial Biology
Q3 Fiscal 2026 Earnings Call, May 6, 2026
Bio-Techne posted another disappointing quarter, reporting a 2% organic revenue decline for Q3 fiscal 2026, with total revenue of $311.4 million. The headline number was cushioned by management's now-familiar caveat around timing headwinds — a 3% drag from two large cell therapy customers who received FDA Fast Track Designation and a 1% impact from an OEM commercial supply order that shifted from Q3 into Q2 — bringing the adjusted underlying organic growth to positive 2%. The problem is that investors have heard this story before, and the emerging biotech end market, which management had expected to stabilize, instead stepped down meaningfully, becoming the central disappointment of the call.
The Biotech Surprise: Management Admits It Got the Call Wrong
The most candid moment on the call came when CEO Kim Kelderman acknowledged the degree to which the biotech end market blindsided the company. Emerging biotech revenue declined high single digits in the quarter, deteriorating from the negative mid-single-digit performance seen in each of the prior two quarters. Management had anticipated a modest improvement to negative low single digits, pointing to strong biotech funding trends, stabilizing interest rates, and rising M&A and licensing activity as constructive signals. Instead, the opposite happened.
The deeper explanation came when Kelderman broke down funding by stage: "Funding was substantially up in late-stage biotech, but early-stage biotech, where a larger portion of our core reagents have a direct read on, that early-stage funding was actually down if you tease that apart." He elaborated further, noting that early-stage discovery has dropped from approximately 25% of total biotech funding allocation to just 18%, with clinical-stage work absorbing the difference. This is a meaningful structural nuance that explains why Bio-Techne's core reagents — proteins, antibodies, and ELISA assays that feed into discovery workflows — have been under disproportionate pressure relative to peers with a heavier clinical mix.
CFO Jim Hippel was equally frank, describing the situation as getting "the cart a little too far ahead of the horse." He noted that historically the lag between biotech funding and customer spending has ranged from one to four quarters, with a mean of two to three quarters. With only two quarters of strong funding in the books, Bio-Techne is sitting right at that median inflection point with no confirmed pickup yet. Hippel's base case for Q4 is that biotech spending stays at Q3 levels, with any improvement representing potential upside rather than a base expectation.
Core Reagents Under Pressure, But Not a Share Loss Story
The core portfolio of over 6,000 proteins and 400,000 antibody types declined mid-single digits in Q3, or low single digits after stripping out the OEM commercial supply timing impact. Management was asked directly by Puneet Souda of Leerink Partners whether the weakness reflects competitive share loss, given that at least one peer in the flow cytometry space is showing growth. Kelderman pushed back, noting that Bio-Techne is lapping nearly 20% growth in the comparable quarter last year, a significantly harder comparison than those peers face. Hippel added an important clarification: after removing the large OEM customer timing impact, the proteins and antibodies portfolio specifically grew low single digits in Q3, an important distinction that the headline core reagent number obscures.
GMP Cell Therapy: The Underlying Story Remains Compelling
Beneath the noise of the two Fast Track Designation customers — whose accelerated clinical timelines reduced near-term GMP reagent pull-through — the rest of the GMP protein portfolio grew nearly 50% year-over-year. This is the number that matters most for understanding Bio-Techne's position in the cell therapy supply chain. The customer base now spans over 700 clients, with the total count growing roughly 3% despite some churn as earlier-stage programs that failed to scale exited the funnel. There are currently 85 programs in clinical stage, with 18 now in Phase II versus 15 previously, and six in Phase III. Kelderman framed the underlying demand driver clearly: "Customers going deeper into their projects and spending more is clearly the driver."
The two Fast Track customers who created the near-term headwind are expected to reduce their drag to approximately 150 basis points in Q4, down from 300 basis points in Q3, and will roll fully out of comparisons entering fiscal 2027. This is a meaningful relief valve for reported growth rates heading into next year.
Wilson Wolf, in which Bio-Techne owns 20% with an option to acquire the remainder by end of calendar 2027, continues to perform well despite the difficult funding backdrop, delivering low double-digit growth on a trailing twelve-month basis with EBITDA margins above 70%. The roughly 50% attachment rate of Bio-Techne's cytokines and proteins with Wilson Wolf's G-Rex bioreactor placements creates a durable cross-sell flywheel that management believes will compound as more programs reach commercial scale.
Spatial Biology Momentum Builds, COMET Exits Quarter With Record Backlog
The Diagnostics and Spatial Biology segment was the relative bright spot, delivering 3% organic growth. COMET, the multiomic spatial platform, grew over 65% and exited Q3 with another record backlog. Notably, the first COMET system was installed in China during the quarter, opening a geography that is showing broad-based momentum across biopharma, CRO, and academic end markets. The RNAscope in situ hybridization portfolio improved to high single-digit growth, driven by EMEA and Asia adoption and increasing penetration into U.S. clinical diagnostics. Segment operating margin expanded to 12.1% from 9.4% a year ago, aided by the divestiture of Exosome Diagnostics and ongoing productivity initiatives, with management guiding for continued margin expansion as COMET scales.
The company cited a specific external validation of the platform's relevance in AI-driven biology: a published collaboration between Providence Health and Microsoft on the GigaTIME AI framework, which used COMET-generated datasets to convert traditional pathology images into virtual three-dimensional tissue representations. Management's argument that high-quality biological data generation is a durable tailwind for spatial biology is increasingly credible as AI adoption accelerates in drug discovery workflows.
Proteomic Analysis and Ella Show Encouraging Signals
Within the Protein Sciences segment, proteomic analysis instruments delivered mid-single-digit growth, led by the Ella benchtop immunoassay platform. Ella's three-year CAGR in neurology assays has reached 50%, driven by the platform's utility in blood-based neurological biomarker analysis. The recent launch of ultrasensitive capabilities and CE-IVD marking for European clinical use expand Ella's addressable market and provide a pathway toward recurring consumable revenue in regulated clinical settings. The Maurice biologic characterization platform drove double-digit growth in both instruments and consumables, reflecting deepening embedded use in biopharma manufacturing quality control workflows.
Management views both Ella and Maurice — along with COMET — as early-cycle indicators for market recovery. "Those two growth vectors for us are where we are kind of indicators for us when we start to see the markets come back, that's where the money often flows first," Hippel explained. The fact that U.S. academic spending on proteomic analysis and spatial biology grew double digits in Q3 was cited as evidence that academic end market confidence is genuinely returning, even if biotech has yet to follow.
Financials: Margins Resilient, Balance Sheet Clean
Adjusted operating margin came in at 34.2%, down 70 basis points year-over-year but representing a 310 basis point sequential improvement from Q2, demonstrating that the cost discipline program is functioning. Adjusted gross margin of 70.4% was down 120 basis points year-over-year on unfavorable product mix, though up 190 basis points sequentially. Adjusted EPS of $0.53 was down $0.03 year-over-year. The balance sheet is clean: bank debt declined $60 million sequentially to $200 million, total leverage is well below 1x EBITDA, and the company generated $86.7 million in operating cash flow during the quarter. Management flagged M&A as the top capital allocation priority, consistent with prior commentary, and the Wilson Wolf acquisition option remains on track.
For Q4, Bio-Techne guided to approximately flat organic growth, with roughly 100 basis points of operating margin expansion year-over-year. The guidance implies that absent a positive biotech surprise, the company will finish fiscal 2026 having delivered a year of largely stagnant top-line performance, even after accounting for the company-specific timing headwinds.
Fiscal 2027: Management Sets the Bar at Mid-Single Digits
When pressed directly by Souda on whether Bio-Techne can still achieve mid-single-digit growth in fiscal 2027, Hippel responded without hedging: "Yes, we'd be disappointed if we didn't do at least mid-single-digit growth because all the indicators are pointing towards a gradual normalization of the market." He underscored that excluding the three customer-specific timing issues, the underlying business would have grown low single digits even in Q3's difficult environment. The cell therapy headwind rolls off entirely entering fiscal 2027, OEM timing normalizes, and the 2-to-3 quarter biotech funding lag places an inflection squarely in the first half of fiscal 2027. Large pharma, now six consecutive quarters of double-digit growth, shows no signs of slowing. China is growing for the fourth consecutive quarter with on-the-ground momentum described as broad-based. The setup, on paper, is constructive. The credibility question is whether management's read on biotech timing is any better now than it was a quarter ago.
Bio-Techne Corporation Deep Dive
Business Model and Revenue Generation
Bio-Techne Corporation operates as a fundamental enabler of the life sciences industry, effectively supplying the mission-critical picks and shovels required for biological discovery, therapeutic development, and clinical diagnostics. The company categorizes its operations into two primary reporting segments. The Protein Sciences segment, which generates approximately three-quarters of total revenue, functions as the economic engine of the firm. This division houses an immense catalog of bioactive recombinant proteins, antibodies, and immunoassays, alongside the ProteinSimple franchise of automated analytical instruments such as the Jess, Wes, and Simple Plex platforms. These instrument systems establish an installed base that methodically pulls through high-margin proprietary consumables. The remaining quarter of the business sits within the Diagnostics and Spatial Biology segment. This division encompasses molecular diagnostics controls and a rapidly scaling spatial multi-omics portfolio, combining the gold-standard RNAscope transcriptomic technology with the recently integrated Lunaphore automated hardware. In a notable strategic shift in late 2025, Bio-Techne divested its Exosome Diagnostics CLIA-certified laboratory business, pivoting the segment away from capital-intensive, lower-margin service models to concentrate exclusively on highly scalable, high-margin product and reagent workflows.
Market Positioning and Competitive Landscape
The company serves a diverse ecosystem of end-users anchored by academic researchers, emerging biotechnology ventures, and large pharmaceutical companies. Current market dynamics reflect a bifurcation in customer behavior; while large pharma customers have demonstrated highly resilient demand, recently posting a sixth consecutive quarter of double-digit growth for Bio-Techne, the emerging biotech segment remains constrained by a protracted macroeconomic funding squeeze. In the broader life sciences tools market, Bio-Techne squares off against industry heavyweights such as Thermo Fisher Scientific and Merck KGaA, which leverage massive scale and bundled service offerings to lock in comprehensive institutional accounts. In the specialized reagent space, the competitive temperature has risen sharply following Danaher's $5.7 billion acquisition of Abcam. Abcam holds a leading 10 percent share of the highly fragmented research antibody market and is now fully backed by Danaher's formidable global distribution machinery. Bio-Techne commands approximately 5 percent of the antibody market but maintains dominant leadership in other core areas. In the premium cytokine and growth factor segment, Bio-Techne controls an estimated 25 percent global market share. More broadly, the global recombinant proteins market remains moderately concentrated, with the top five players, including Thermo Fisher, Merck KGaA, and Bio-Techne, capturing roughly 60 percent of total industry revenues.
Competitive Advantages
Bio-Techne's economic moat rests on three structural pillars: unparalleled brand equity, immense catalog scale, and insurmountable switching costs. The company's legacy R&D Systems brand is universally recognized as the gold standard for bioactive proteins and cytokines, a reputation painstakingly forged over decades of peer-reviewed validation. With a catalog exceeding 500,000 products and over one million distinct SKUs, Bio-Techne provides a centralized discovery hub that smaller, fragmented competitors simply cannot replicate. Furthermore, life sciences workflows are notoriously sticky. Once a specific Bio-Techne reagent or antibody is embedded into an academic paper, an FDA regulatory filing, or a clinical manufacturing standard operating procedure, the switching costs become prohibitive. Researchers and biomanufacturers will not risk assay failure, yield reduction, or regulatory delays to save marginal costs on foundational inputs. This extreme pricing power is clinically evident in the firm's financial profile. Bio-Techne consistently translates this moat into structural gross margins approaching 70 percent and adjusted operating margins hovering between 30 percent and 34 percent, distinguishing the firm as one of the most profitable entities in its peer group.
Industry Dynamics
Navigating the current life sciences landscape requires managing acute cyclical headwinds while positioning for powerful secular tailwinds. A primary threat to Bio-Techne is the suppressed funding environment for early-stage science. While top-tier biopharma continues to deploy capital, the prolonged contraction in venture funding for emerging biotech has suppressed broad-based demand for foundational research tools, directly impacting Bio-Techne's organic growth trajectory. Furthermore, the aggressive consolidation by mega-cap peers threatens to commoditize lower-tier reagent segments through sheer volume, bundling, and advanced digital procurement platforms. Conversely, structural opportunities remain highly attractive. The rapid maturation of cell and gene therapies provides a significant, multi-year tailwind for Bio-Techne's GMP-grade proteins. As therapeutic developers transition from early-stage clinical research to commercial-scale manufacturing, their requirements shift from research-use-only reagents to stringently regulated GMP materials. This transition unlocks high-value, long-duration commercial supply contracts, a dynamic that recently drove 50 percent underlying growth in Bio-Techne's GMP protein portfolio. Additionally, management has identified encouraging momentum in the Asia-Pacific region, providing a geographic counterweight to domestic academic and biotech sluggishness.
Next-Generation Growth Drivers and Disruptive Threats
To catalyze future revenue acceleration, Bio-Techne is aggressively indexing toward the nascent spatial biology market, a sub-sector with an estimated addressable market exceeding $12 billion. The company is scaling its Lunaphore COMET platform, an automated hardware system that enables researchers to map up to 24 proteins and 12 RNA targets simultaneously on a single tissue slide at single-cell resolution. By bundling this hardware with pre-validated, off-the-shelf antibody panels, Bio-Techne is transitioning from a mere component supplier to an integrated spatial multi-omics workflow provider. However, the spatial biology arena is hyper-competitive and highly vulnerable to disruptive innovation. New entrants like Parse Biosciences and Vizgen are aggressively pushing the technological envelope. These agile start-ups are introducing highly scalable, instrument-free combinatorial barcoding techniques and ultra-high-plex single-cell mapping platforms. By lowering the capital expenditure barriers to entry and radically expanding plex capabilities, these disruptive innovators threaten to leapfrog established hardware-based approaches, forcing Bio-Techne to continuously defend the technical superiority and workflow convenience of its COMET and RNAscope franchises.
Management Track Record
The current operational narrative is shaped by CEO Kim Kelderman, who assumed leadership in early 2024. As the former head of the Diagnostics and Genomics segment, Kelderman orchestrated the critical Lunaphore acquisition and has brought a clinical, margin-focused discipline to the executive suite. His tenure has been characterized by proactive portfolio optimization, most notably the decisive divestiture of the Exosome Diagnostics CLIA business in late 2025. By shedding this capital-intensive service unit, Kelderman demonstrated a willingness to sacrifice top-line vanity for structural profitability, actively rotating capital toward higher-margin, non-CLIA growth vectors. However, his execution track record is currently being tested by a highly dynamic macro environment. The most recent fiscal quarter in early 2026 revealed a slight organic revenue contraction, driven by unfavorable prior-year comparisons from lumpy GMP fast-track orders and sustained biotech softness. While this prompted a severe near-term equity re-rating, Kelderman has successfully maintained double-digit growth in large pharma accounts and driven mid-teens expansion in spatial biology, indicating that the underlying operational machinery remains sound despite surface-level volatility.
The Scorecard
Bio-Techne occupies an enviable structural position within the life sciences ecosystem, functioning as an essential provider of validated biological inputs in a market characterized by immense switching costs. The transition from a fragmented reagent supplier to a comprehensive workflow solutions provider is well underway, anchored by strategic acquisitions in spatial multi-omics and a focused divestiture of non-core diagnostic laboratory services. While near-term cyclicality in emerging biotech funding and lumpy clinical manufacturing orders have obfuscated the underlying growth trajectory, the company's entrenched 25 percent market share in premium cytokines and its interlocking consumable-instrument ecosystem ensure an exceptionally resilient margin profile.
The primary risks reside in the accelerated consolidation of direct competitors, particularly Danaher's integration of Abcam, and the relentless pace of innovation from disruptive entrants in the spatial biology space. Nevertheless, management's disciplined capital allocation under CEO Kim Kelderman and the structural pivot toward high-growth, commercial-stage cell and gene therapy manufacturing supply provide a highly credible roadmap for long-term value compounding. As the broader biotechnology funding environment normalizes, Bio-Techne's foundational utility in drug discovery and therapeutic development should translate into sustained, highly profitable growth.